Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Neoplasm Metastasis

Brain Neoplasms

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series.

Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series.

Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed approximately 1-2 weeks prior to FSRT, during the last week of RT but before the last fraction and 1 month after RT. The MRI scan will include a routine clinical MRI series.

Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.

Single Fraction Stereotactic Radiosurgery (SRS)

Fractionated Whole Brain Radiation Therapy (WBRT)

Fractionated Stereotactic Radiation Therapy (FSRT)

MRI scans will include a routine clinical MRI series.

Magnetic Resonance Imaging (MRI) Assessments

Yue Cao, Ph.D.

This study aims to assess changes in vascular permeability in the brain tumor, and in the surrounding brain, due to radiation therapy, using Magnetic Resonance Imaging (MRI).

MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy

Fifty metastatic lesions from 21 patients received WBRT and 14 lesions from 9 patients treated by SRS were analyzed. Permeability of BTB (Blood-Tumor-Barrier) was quantified by the transfer constant, Ktrans, derived from dynamic contrast enhanced (DCE)-MRI that were acquired pre, 1-2 weeks after starting, and 1-month post-radiotherapy. A percentage volume of the BM with Ktrans \>0.005 min-1 (%Vall) was used to evaluate the extent of BTB opening pre-RT and subsequent changes after receiving radiotherapy. The 50 lesions, from the 21 patients treated with Whole Brain Radiation Therapy, were divided into two subgroups: low-leaky (%Vall \<50%) and high-leaky, based upon pre-RT measurements. Of the 50 lesions, 7 were classified as low leaky and 43 were classified as high leaky. All 14 SRS lesions were classified as high leaky.

An in-house program, based on a general kinetic model, along with an MRI contrast agent, Gadopentetic Acid (Gd-DTPA), will be used to estimate vascular permeability (per minute).

Effect of radiation dose on vascular permeability (per minute) of the Blood Tumor Barrier (BTB)/Blood Brain Barrier (BBB). Permeability of BTB was quantified by Ktrans.

University of Michigan Rogel Cancer Center

Only adverse events recorded in the medical chart as related to the study MRI scan or neurocognitive testing) were collected per protocol. No Non-Serious or Serious Adverse Events were reported to the study team.

Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed approximately 1-2 weeks prior to SRS, and 1-2 weeks and 1 month after SRS. The MRI scan will include a routine clinical MRI series.

Single Fraction Stereotactic Radiosurgery (SRS): Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.

Magnetic Resonance Imaging (MRI) Assessments: MRI scans will include a routine clinical MRI series.

Stereotactic Radiosurgery (SRS)

Patients with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed approximately 1-2 weeks prior to RT, at the end of RT and 1 month after RT. The MRI scan will include a routine clinical MRI series.

Fractionated Whole Brain Radiation Therapy (WBRT): Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.

Magnetic Resonance Imaging (MRI) Assessments: MRI scans will include a routine clinical MRI series.

Whole Brain Radiation Therapy

Total

Age, Continuous

Sex: Female, Male

Dr. Yue Cao

Pre-RT

1-2 Weeks Post RT

1 Month Post RT

Patients with brain metastases receiving single fraction Stereotactic Radiosurgery (SRS). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed prior to SRS, at 1-2 weeks post SRS, and 1 month after SRS. The MRI scan will include a routine clinical MRI series.

Single Fraction Stereotactic Radiosurgery (SRS): Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.

Magnetic Resonance Imaging (MRI) Assessments: MRI scans will include a routine clinical MRI series.

43 Lesions from 21 Patients were highly leaky.

Participants with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed prior to RT, at 1-2 weeks post RT and 1 month after RT. The MRI scan will include a routine clinical MRI series.

An in-house program developed to estimate vascular permeability voxel-by voxel was used to classify this WBRT group as " High Leaky" (more permeable) based upon their baseline MRI scan.

Whole Brain Radiation Therapy (High Leaky Lesions)

7 Lesions from 21 Patients were classified as low leaky.

Participants with brain metastases receiving fractionated (spread out over time) Whole Brain Radiation Therapy (WBRT). This intervention is not assigned by the investigator. Treatment has been decided prior to study enrollment.

MRI scans will be performed prior to RT, at 1-2 weeks post RT and 1 month after RT. The MRI scan will include a routine clinical MRI series.

An in-house program developed to estimate vascular permeability voxel-by voxel was used to classify this WBRT group as " High Leaky" (more permeable) based upon their baseline MRI scan.

Whole Brain Radiation Therapy (Low Leaky Lesions)

Fifty metastatic lesions from 21 patients received WBRT and 14 lesions from 9 patients treated by SRS were analyzed. All lesions were classified as high or low leaky dependent upon pre-RT permeability values.

Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1

Change in Magnitude and Regional Variability of Blood Tumor Barrier (BTB)/Blood Brain Barrier (BBB) Permeability (Per Minute) in Tumor, Tumor Margin, Normal Brain and Brain Metastases

Change in Mean K^Trans During and After Radiation Therapy

Patients with brain metastases receiving fractionated (spread out over time) Stereotactic Radiation Therapy (FSRT). This intervention has not been assigned by the investigator. Treatment is decided prior to enrollment.

Spots Global Cancer Trial Database for MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy

Trial Identification

Conditions

Interventions

Study Description

Keywords

Eligibility

Locations

Contact Details

Useful links and downloads for this trial